Provided by Tiger Fintech (Singapore) Pte. Ltd.

Exelixis

46.26
+1.613.61%
Post-market: 46.510.2500+0.54%17:10 EDT
Volume:10.31M
Turnover:482.77M
Market Cap:12.62B
PE:20.99
High:48.85
Open:44.55
Low:44.21
Close:44.65
Loading ...

Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now?

Insider Monkey
·
02 Mar

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

Zacks
·
26 Feb

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

Business Wire
·
26 Feb

4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty

Zacks
·
26 Feb

EXEL or TECH: Which Is the Better Value Stock Right Now?

Zacks
·
25 Feb

Wells Fargo Downgrades Exelixis to Equalweight From Overweight, Price Target is $36

MT Newswires Live
·
24 Feb

Exelixis Cut to Equal-Weight From Overweight by Wells Fargo

Dow Jones
·
24 Feb

Wells Fargo downgrades Exelixis, says take profits after rally

TIPRANKS
·
24 Feb

Exelixis downgraded to Equal Weight from Overweight at Wells Fargo

TIPRANKS
·
24 Feb

Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks

Insider Monkey
·
24 Feb

Why Exelixis Stock Trounced the Market on Thursday

Motley Fool
·
22 Feb

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Benzinga
·
22 Feb

Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point

Simply Wall St.
·
21 Feb

Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?

Zacks
·
18 Feb

International Markets and Exelixis (EXEL): A Deep Dive for Investors

Zacks
·
17 Feb

Exelixis announces final five-year follow-up results from CheckMate -9ER

TIPRANKS
·
17 Feb

Exelixis Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.
·
16 Feb

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Zacks
·
14 Feb

Exelixis Is Maintained at Equal-Weight by Barclays

Dow Jones
·
13 Feb

Exelixis Hold Rating Maintained Amidst Stable Financials and Awaited Trial Data

TIPRANKS
·
13 Feb